Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer
Related Experiment Video
Updated: Jun 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Werner Scheithauer1, Wolff Schmiegel
1Division of Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Austria. werner.scheithauer@meduniwien.ac.at
Abstract:
The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Drugs for Treatment of Ulcerative Colitis in IBD
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
